Page 67 - Read Online

Page 14 of 15 Wu et al. Hepatoma Res 2023;9:6 https://dx.doi.org/10.20517/2394-5079.2022.37

48. Fenton SE, Kircher SM, Mulcahy MF, et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in
patients with advanced hepatocellular cancer. JCO 2021;39:e16183-e16183. DOI
49. Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular
carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:1025-35. DOI PubMed
50. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses
of a phase III trial. J Hepatol 2012;57:821-9. DOI PubMed
51. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients
with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27. DOI PubMed
52. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a
sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist
2012;17:359-66. DOI PubMed PMC
53. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the
SPACE trial. J Hepatol 2016;64:1090-8. DOI PubMed
54. Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable
hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol
2017;2:565-75. DOI PubMed
55. Erhardt A, Kolligs F, Dollinger M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter,
phase II SOCRATES trial. Cancer Chemother Pharmacol 2014;74:947-54. DOI PubMed
56. Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and
effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 2015;136:1458-67. DOI
PubMed
57. Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with
unresectable hepatocellular carcinoma. J Hepatol 2012;56:1336-42. DOI PubMed
58. Kudo M, Ueshima K, Ikeda M on behalf of the TACTICS study group, et al. Randomised, multicentre prospective trial of transarterial
chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Gut 2020;69:1492-1501. DOI PubMed PMC
59. Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced
hepatocellular carcinoma: the phase III STAH trial. J Hepatol 2019;70:684-91. DOI
60. Bonifazi M, Rossi M, Moja L, et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and
safety. Oncologist 2012;17:117-24. DOI PubMed PMC
61. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody
bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009;29:284-90. DOI
PubMed
62. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced
hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7:e49717. DOI PubMed PMC
63. Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment
of hepatocellular cancer: a pilot study. BMC Cancer 2012;12:16. DOI PubMed PMC
64. Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular
carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. DOI PubMed PMC
65. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular
carcinoma. J Clin Oncol 2020;38:2960-70. DOI PubMed PMC
66. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma
(AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9. DOI PubMed
67. Chan SL, Yeo W, Mo F, et al. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization
and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer 2017;123:3977-85. DOI PubMed
68. Kang YK, Yau T, Park JW, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line
treatment of advanced hepatocellular carcinoma. Ann Oncol 2015;26:2457-63. DOI PubMed
69. Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular
carcinoma: a randomized phase III trial. Hepatology 2014;60:1697-707. DOI PubMed
70. Kudo M, Cheng AL, Park JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with
unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet Gastroenterol Hepatol 2018;3:37-46. DOI PubMed
71. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced
hepatocellular carcinoma. J Hepatol 2017;66:545-51. DOI PubMed PMC
72. Ji Q, Fu Y, Zhu X, Wang L, Ling C. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell
immunotherapy in primary hepatocellular carcinoma. J BUON 2021;26:235-242. PubMed
73. Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with
systemic therapy in hepatocellular carcinoma (HCC). Cancers (Basel) 2019;11:1085. DOI PubMed PMC
74. Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced